Drug intelligence / Profile preview

AST-120 + prednisolone

Development stage: Unknown
Lead developer: Kureha
Modality: Small Molecules
Administration: Oral

Overview

A combination of AST-120 (an oral spherical activated carbon adsorbent) and prednisolone (a corticosteroid). AST-120 works by adsorbing uremic toxins such as indoxyl sulfate in the intestines, potentially delaying the progression of chronic kidney disease and improving uremic symptoms. Prednisolone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties.

Targets

PCS (p-Cresyl sulfate)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on AST-120 + prednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AST-120 + prednisolone.

Explore the full profile